![]() |
![]() |
|
Health Topics Category Index Health Topics for Neurological Health
|
Multiple SclerosisMultiple Sclerosis (MS) is an acquired inflammatory, demylenating disease of the Central Nervous System (CNS). MS is a leading cause of disability in young adults. It strikes people in the prime of their lives, usually between 20 and 40 years of age. It is estimated that more than 400,000 individuals, two-thirds of whom are female, in the United States are afflicted by the disease, at a national cost of nearly $10 billion per year. In MS, cells of the immune system invade the CNS and destroy myelin (the fatty material that insulates the neurons in the brain and spinal cord), leading to demyelination of the axon and damage to the axon itself. In response, other CNS cells produce a hardened sclerotic lesion (plaque) around the multiple demyelinated sites. Not all lesions are associated with neurological dysfunction and, depending on their location, areas of demyelination may not cause clinical symptoms or signs. Such lesions are referred to as "silent lesions." Etiology of MS The cause of MS remains unknown. Both genetic and environmental factors have been implicated in the disease. Some combination of genetic susceptibility and one or more environmental triggers appears to be the most likely explanation. Clinical Features of MS
Sensory Problems: Natural Course of MS The natural course of MS is highly variable and it is impossible to predict the nature, severity, or timing of progression in a given patient; however, there are a few guidelines to follow. For instance, a patient with numbness or tingling (sensory problems) tends to have a better prognosis than those with spasticity or paralysis (balance or coordination problems). Another factor that influences prognosis is age of onset. Disease progression tends to be more rapid in patients who experience their first symptoms after age 40. Other factors predictive of rapid progression include male gender, frequent attacks, and burden of disease as detected by magnetic resonance imaging (MRI). The course of MS over the first 5 years can provide a clue to the progression of the disease over the next 10 years. In a series of patients, 90% of those with minimal disability 5 years after disease onset were still ambulatory at 15 years. Classifications of MS Clinically definite MS is further categorized according to disease course. Relapsing-remitting MS is characterized by symptoms that develop over a period of a few hours to a few days, followed by recovery and a stable course between relapses. Approximately 80% of patients are initially diagnosed with relapsing-remitting MS. Almost 50% of patients with relapsing-remitting MS eventually develop secondary-progressive (SP) MS characterized by gradual neurological deterioration with or without superimposed acute relapses. If there is continual disease progression from onset with only minor fluctuation the classification becomes primary-progressive (PP). PP-MS occurs in approximately 10% of patients, mainly those who are older than 40 years at onset. Progressive-relapsing MS, a rare form of the disease, is characterized by gradual neurological deterioration from the onset of symptoms and subsequent superimposed relapses.
Diagnosis and Treatment of MS A diagnosis of MS should be confirmed by a qualified neurologist, who would subsequently recommend appropriate treatments accordingly. Realistic Expectations Despite being told that none of these drugs is a cure for MS and that therapy is unlikely to reverse existing disabilities, patients with MS often hope that their disabilities will disappear and that no further exacerbation will occur. Failure to achieve these outcomes is likely to be very discouraging, therefore patients and their families require continual support and understanding. Education is crucial to maintaining patient compliance with treatment. In addition to the patient-support program provided by each drug supplier, the individual health care provider will be looked to for guidance on all aspects of treatment. Additional Resources:
Last Reviewed 2005 Source: E. Torage Shivapour, M.D. Disclaimer: This content is reviewed periodically and is subject to change as new health information becomes available. The information provided is intended to be informative and educational and is not a replacement for professional medical evaluation, advice, diagnosis or treatment by a healthcare professional. |
||||
| Last modification date:
Mon Aug 7 13:13:27 2006
|
|||||